Literature DB >> 18443363

Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.

Sunil Bhandari1, Neil Watson, Ervine Long, Steve Sharpe, Wenwen Zhong, Shang-Zhong Xu, Stephen L Atkin.   

Abstract

Somatostatin mediates inhibitory functions through five G protein-coupled somatostatin receptors (sst1-5). We used immunohistochemistry, immunofluorescence, and RT-PCR to determine the presence of somatostatin receptors sst1, sst2A, sst2B, sst3, sst4, and sst5 in normal and IgA nephropathy human kidney. All somatostatin receptors were detected in the thin tubules (distal convoluted tubules and loops of Henle) and thick tubules (proximal convoluted tubules) in the tissue sections from nephrectomy and biopsy samples. Immunopositive sst1 and sst4 staining was more condensed in the cytoplasm of tubular epithelial cells. In normal kidney tissue sections, podocytes and mesangial cells in the glomeruli stained for sst1, sst2B, sst4 and sst5, and stained weakly for sst3. In IgA kidney tissue, the expression of somatostatin receptors was significantly increased with particular immmunopositive staining for sst1, sst2B, sst4, and sst5 within glomeruli. In the epithelial cells, the staining for sst2B and sst4 in proximal tubules and sst1, sst2B, and sst5 in distal tubules was increased. The mRNA expression of sst1-5 was also detected by RT-PCR. Somatostatin and all five receptor subtypes were ubiquitously distributed in normal kidney and IgA nephropathy. The increased expression of somatostatin receptors in IgA nephropathy kidney might be the potential pathogenesis of inflammatory renal disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443363      PMCID: PMC2443611          DOI: 10.1369/jhc.2008.950998

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  58 in total

Review 1.  Peptides as regulators of the immune system: emphasis on somatostatin.

Authors:  S Krantic
Journal:  Peptides       Date:  2000-12       Impact factor: 3.750

2.  Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study.

Authors:  Yusuke Taniyama; Takashi Suzuki; Yoshiki Mikami; Takuya Moriya; Susumu Satomi; Hironobu Sasano
Journal:  Endocr J       Date:  2005-10       Impact factor: 2.349

3.  Agonist-induced endocytosis of rat somatostatin receptor 1.

Authors:  Dirk Roosterman; Oliver J Kreuzer; Nicole Brune; Graeme S Cottrell; Nigel W Bunnett; Wolfgang Meyerhof; Martin Steinhoff
Journal:  Endocrinology       Date:  2006-12-14       Impact factor: 4.736

4.  Specific inhibition of aldosterone responses to endogenous and exogenous angiotensin II by somatostatin.

Authors:  C R Jones; J A Millar; C Lawrie; D J Sumner; J L Reid
Journal:  Clin Endocrinol (Oxf)       Date:  1984-09       Impact factor: 3.478

5.  Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.

Authors:  Edgar J Rolleman; Eric P Krenning; Bert F Bernard; Monique de Visser; Magda Bijster; Theo J Visser; Marcel Vermeij; Jan Lindemans; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-22       Impact factor: 9.236

6.  Effect of a new somatostatin analogue SMS 201-995 (Sandostatin) on the renin-aldosterone axis.

Authors:  C Sieber; M Gnädinger; E Del Pozo; S Shaw; P Weidmann
Journal:  Clin Endocrinol (Oxf)       Date:  1988-01       Impact factor: 3.478

7.  Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.

Authors:  S Schulz; S U Pauli; S Schulz; M Händel; K Dietzmann; R Firsching; V Höllt
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

8.  Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management.

Authors: 
Journal:  Urol Oncol       Date:  2000-04-01       Impact factor: 3.498

9.  Somatostatin-like immunoreactivity in the glomerulus of rat kidney.

Authors:  K Kurokawa; G W Aponte; S Fujibayashi; T Yamada
Journal:  Kidney Int       Date:  1983-12       Impact factor: 10.612

10.  Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies.

Authors:  S Schulz; S Schulz; J Schmitt; D Wiborny; H Schmidt; S Olbricht; W Weise; A Roessner; C Gramsch; V Höllt
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

View more
  23 in total

Review 1.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

2.  Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Authors:  Esther Meijer; Folkert W Visser; Rene M M van Aerts; Charles J Blijdorp; Niek F Casteleijn; Hedwig M A D'Agnolo; Shosha E I Dekker; Joost P H Drenth; Johan W de Fijter; Maatje D A van Gastel; Tom J Gevers; Marten A Lantinga; Monique Losekoot; A Lianne Messchendorp; Myrte K Neijenhuis; Michelle J Pena; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Jack F Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  JAMA       Date:  2018-11-20       Impact factor: 56.272

Review 3.  ADPKD current management and ongoing trials.

Authors:  Francesca Testa; Riccardo Magistroni
Journal:  J Nephrol       Date:  2019-12-18       Impact factor: 3.902

4.  68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax.

Authors:  Christian Boy; Till A Heusner; Thorsten D Poeppel; Anja Redmann-Bischofs; Nicole Unger; Walter Jentzen; Wolfgang Brandau; Klaus Mann; Gerald Antoch; Andreas Bockisch; Stephan Petersenn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-03       Impact factor: 9.236

5.  Zinc-Chelating Small Molecules Preferentially Accumulate and Function within Pancreatic β Cells.

Authors:  Timothy M Horton; Paul A Allegretti; Sooyeon Lee; Hannah P Moeller; Mark Smith; Justin P Annes
Journal:  Cell Chem Biol       Date:  2018-12-06       Impact factor: 8.116

Review 6.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

7.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Joost P H Drenth; Hedwig d'Agnolo; Niek F Casteleijn; Johan W de Fijter; Tom J Gevers; Peter Kappert; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Vicente E Torres; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2013-12-15       Impact factor: 8.860

8.  Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues.

Authors:  Zoltán Varecza; Krisztián Elekes; Terézia László; Anikó Perkecz; Erika Pintér; Zoltán Sándor; János Szolcsányi; Dániel Keszthelyi; Arpád Szabó; Katalin Sándor; Tamás F Molnár; Zalán Szántó; Judit E Pongrácz; Zsuzsanna Helyes
Journal:  J Histochem Cytochem       Date:  2009-08-17       Impact factor: 2.479

9.  Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Authors:  Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Sergio A Gradilone; Bing Huang; Anatoliy I Masyuk; Marie C Hogan; Vicente E Torres; Nicholas F Larusso
Journal:  Hepatology       Date:  2013-03-06       Impact factor: 17.425

Review 10.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.